Head of Patient Advocacy, Shelagh McKinlay shares her thoughts on a perspective from NICE on the use of patient preference data.
Myeloma patients can now access Isatuximab, Pomalidomide (Imnovid®) and Dexamethasone after it was given a positive opinion through the Early Access to Medicines Scheme (EAMS)
Myeloma patients at first relapse in Scotland will now be able to access the new treatment of daratumumab (Darzalex®), bortezomib (Velcade®) and dexamethasone on the NHS after it was approved for use by the Scottish Medicines Consortium (SMC).
The National Institute of Health and Care Excellence (NICE) has today approved the myeloma treatment lenalidomide (Revlimid®) and dexamethasone for use in treating newly diagnosed patients and patients at first relapse.
Myeloma patients at first relapse in England and Wales will now be able to access the new treatment of daratumumab (Darzalex®), bortezomib (Velcade®) and dexamethasone on the NHS after it was approved for use through the Cancer Drugs Fund (CDF).
The Myeloma UK Patient Advocacy team looks at ‘out-of-hospital’ care and its place at the heart of what NHS England's 10 year plan.
The Myeloma UK Patient Advocacy Team takes a look at the NHS England 10 year plan, and the implications it will have for myeloma patients.
Myeloma UK has celebrated a new milestone after reaching 100 Support Groups across the UK and Ireland.